Table 1.

Patient characteristics for the total population (N=250) and separated into incident cases (enrollment less than 3 months since chronic GVHD diagnosis) and prevalent (>3 months since chronic GVHD diagnosis)

	Total		Incident		Prevalent
	n	%	n	%	n	%
Median age (yrs), IQR, [range]	250	53 IQR 43-61 [19-79]	148	53 IQR 42-62 [19-79]	102	52 IQR 44-60 [22-74]
Gender
Males	140	56.0	77	52.0	63	61.8
Females	110	44.0	71	48.0	39	38.2
Type of transplant
Myeloablative	114	45.6	65	43.9	49	48.0
Not myeloablative	136	54.4	83	56.1	53	52.0
Conditioning regimens
Myeloablative	134	53.6	79	53.4	55	53.9
Busulfan/cyclophosphamide	57	22.8	34	23.0	23	22.6
Cyclophosphamide/TBI	42	16.8	21	14.2	21	20.6
Treosulfan/fludarabine +/− TBI	26	10.4	18	12.2	8	7.8
Other myeloablative regimen	9	3.6	6	4.0	3	2.9
Not myeloablative	116	46.4	69	46.6	47	46.1
Busulfan/fludarabine	2	0.8	1	0.7	1	1.0
Fludarabine/TBI	101	40.4	60	40.5	41	40.2
Other not myeloablative regimen	13	5.2	8	5.4	5	4.9
Type of donor
Unrelated	150	60.0	93	62.8	57	55.9
Related	97	38.8	52	35.1	45	44.1
Cord blood	3	1.2	3	2.0	0	–
Graft type
Peripheral blood	227	90.8	134	90.5	93	91.2
Bone marrow	20	8.0	11	7.4	9	8.8
Cord blood	3	1.2	3	2.0	0	–
Type of case
Incident	148	59.2		–		–
Prevalent	102	40.8
NIH severity at enrollment
Mild/None	16	6.4	10	6.8	6	5.9
Moderate	132	52.8	69	46.6	63	61.8
Severe	102	40.8	69	46.6	33	32.4
Median time from chronic GVHD diagnosis to enrollment (months), IQR [range]	250	1.7 IQR 0-7.8 [-0.1 - 26.6]	148	0 IQR 0-0.9, [-0.1 - 2.8]	102	8.7 IQR 5.3-14.7, [3.1-26.6]
Median time from transplant to last follow-up (years), IQR [range]	250	5.8 IQR 4.0-7.1, [0.4-29]	148	5.3 IQR 4.0-6.7 [0.4-9.8]	102	6.7 IQR 4.1-7.9, [1.1-29]
Median follow up (years), IQR [range]
All patients	250	4.9 IQR 3.5-6.5, [0.04-9.1]	148	4.6 IQR 3.3-5.9, [0.04-7.9]	102	5.8 IQR 3.7-7.2 [0.6-9.1]
Survivors	177	5.6 IQR 4.5-6.8, [1.0-9.1]	106	5.1 IQR 4.2-6.4, [1.0-7.9]	71	6.4 IQR 5.0-7.6, [1.3-9.1]

Abbreviations: IQR, intra-quartile range; TBI, total body irradiation